Review Article

Induced pluripotent stem cells and derivative photoreceptor precursors as therapeutic cells for retinal degenerations

Rupendra Shrestha¹, Yao-Tseng Wen², Rong-Kung Tsai¹**

¹Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan, ²Institute of Eye Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

ABSTRACT

The visual impairment associated with inherited retinal degeneration and age-related degeneration of photoreceptors is causing substantial challenges in finding effective therapies. However, induced pluripotent stem cell (iPSC)-derived therapeutic cells such as photoreceptor and retinal pigment epithelium (RPE) cells provide the ultimate options in the rescue of lost photoreceptors to improve the visual function in end-stage degeneration. Retinal cells derived from iPSC are therapeutic cells that could be promising in the field of cell replacement therapy and regenerative medicine. This review presents an overview of the photoreceptor degeneration, methods of iPSC generation, iPSC in retinal disease modeling, summarizes the photoreceptor differentiation protocols, and challenges remained with photoreceptor cell replacement for the treatment of retinal diseases. Thus, the burden and increased incidence of visual impairment emphasizes the need of novel therapy, where iPSC-derived photoreceptor and RPE cells proved to be promising for curing the retinal dysfunction and act as renovation in approach to improve visual function.

KEYWORDS: Induced pluripotent stem cells, Photoreceptors, Retinal degeneration, Retinal disease modeling, Transplantation

INTRODUCTION

The ontogenetic of retina presents a unique structure for studying neurogenesis, cellular interactions, and gene influences. The retinal cell fates are determined by the various transcription factors and are generated from the pool of multipotent progenitor cells [1,2]. The retina is formed by the proper organization of specific neurons such as photoreceptors (rod and cone), bipolar, amacrine, horizontal, ganglion cells, and types of glial cell such as Müller glia [3]. The functional light-sensitive photoreceptor cells are responsible for the visual senses of interaction with the environments. However, vision impairment due to degeneration of photoreceptor is affecting more than 43 million people globally with an exponential increase in population with advanced age predominantly over 50 years (WHO, 2016, Visual Impairment and Blindness). The cause of visual impairment is due to the progressive loss of photoreceptors related to genetically heterogeneous disorders. The degeneration of photoreceptors associated with genetic and environmental insults leads to blindness is linked to high metabolic need in the renewal of photoreceptor outer segment discs (OSD) [4]. The photoreceptor degeneration is a complex trait altered due to a large number of variant genes, related to environmental factors and predominantly monogenic inheritance [5,6]. Numerous therapeutic strategies, such as neuroprotective agents, gene therapy, retinal prosthesis, and cell replacement therapy have been developed, and some of them already entered the clinical trials. However, cell therapy is an option for advanced retinal diseases, and challenges persist due to the limited source of therapeutic cells, such as retinal pigment epithelium (RPE) and photoreceptors as shown in Figure 1. In this regard, induced pluripotent stem cells (iPSCs) provide a unique in vitro model that allows the generation of retinal progenitor cells for modeling of retinal degenerative diseases. Retinal cell derivatives generated from iPSCs are useful for drug screening for personalized medicine and effective strategies for cellular therapy in both early and end-stage retinal diseases. Furthermore, modeling of developmental disorders is particularly amenable using iPSCs and their derivatives [7].

In this review, we specially focus and summarize recent perspectives for directed differentiation of photoreceptor cells from iPSC and iPSC-derived photoreceptor transplantation in retinal disease modeling and possibilities for improving the retinal functions. All the information was obtained from the reliable literature sources.
Photoreceptor degeneration

The photoreceptors are exceptionally vulnerable cells in the retina, and progressive degeneration of these cells leads to the irreversible loss of vision. Usually, light-sensing photoreceptors (rods – dim and cones – bright) form the visual transduction cascade to perform specialized visual functions. These cells undergo complex phototransduction mechanism that interlinked with the metabolism of retinoid; thus, high metabolic rate is involved in the retinoid visual cycle at the cellular level, molecular level, and electrophysiology of photoreceptor function [8,9]. The metabolic alteration in retinoid contributes to a high level of susceptibility to genetic defects causing dysfunction or death of photoreceptors. Such anomalies lead to loss of inner retinal connection and alter the neuronal networking cascade. Fortunately, the transplanted photoreceptor precursors from the developing retina can contribute to making single and short synaptic interplay to the optical network for retinal modeling [10].

Several inherited retinal diseases are associated with dysfunction and progressive loss of photoreceptors, such as retinitis pigmentosa [11], age-related macular degenerations [12], and Leber’s congenital amaurosis (LCA) [13]. Among them, retinitis pigmentosa is the leading cause of untreatable blindness that is characterized by gradual constriction of visual field. Moreover, the loss of photoreceptors in inherited retinal diseases does not have genotype–phenotype correlation due to extensive genetic heterogeneity. Inherited retinal diseases, such as macular degeneration, retinitis pigmentosa, and Usher syndrome constitute a genetically heterogeneous group with almost 293 human genetic loci and more than 256 genes identified so far (Retnet; https://sph.uth.edu/retnet/sym-dis.htm) [14].

Pluripotent stem cells and cellular reprogramming

Pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and iPSCs, provide a unique in vitro model for generating the therapeutic cells, such as photoreceptor and RPE for cell replacement therapy in retinal degenerative diseases. Here, we specifically focus on iPSCs generated from somatic cells by cellular reprogramming using defined transcription factors.

Induced pluripotent stem cells

iPSC was an innovative discovery by Takahashi and Yamanaka in 2006, where mouse embryonic/skin fibroblasts and adult human fibroblasts were converted into PSCs by the overexpression of defined transcription factors, such as Oct4, Sox2, Klf4, and c-Myc using the retroviral system [15,16]. These cells were morphologically identical and showed similar pluripotent gene expression like in ESCs system [15,16]. Furthermore, Yu et al. used other sets of defined factors, such as Oct4, Sox2, Nanog, and LIN28 using lentivirus to generate iPSCs from foreskin fibroblasts [17]. These iPSCs showed the expression of pluripotency genes and potential to differentiate into developmental germ layers (endoderm, mesoderm, and ectoderm) investigated using standard in vivo teratoma assay and alternative in vitro embryoid body formation [16]. iPSCs have been generated from somatic cells of different mammals, such as mice [18], human [16], monkeys [19], and pigs [20]. These iPSCs showed similar characteristic features of PSCs; however, cell reprogramming efficiency differs among different cell origin, cell types, and no consensus on the most consistent protocol for generating the reliable and safest iPSCs [21]. Still, iPS technology has been revolutionizing the stem cell research and therapy for regenerative medicine.
Alternative methods for induced pluripotent stem cell generation

Since the discovery of iPSC technology, reprogramming protocol improvements are increasing to achieve efficient derivation and to maintain the normal genomic integrity. Recently, iPSC methods are available as commercial kit, but they do require reliability with regard to efficiency and reproducibility of reprogramming somatic cells into iPSC for biomedical uses in routine work [22]. Different methods for cellular reprogramming are summarized and extensively reviewed [23] [Table 1].

Molecules for enhancing reprogramming efficiency

Generation of iPSCs is time-consuming, and the efficiency varies with cell types and without consistent protocols. Thus, for clinical application of iPSCs, it is necessary to overcome the limitations of low efficiency. Numerous lists of small molecules, growth factors, microRNAs, and siRNAs have been suggested to enhance the efficiency of cellular reprogramming based on several well-known mechanisms [36,37]. Some of the commonly used small molecules are listed in Table 2.

Molecular basis of genomic instability of induced pluripotent stem cell

Genomic instability acquired during forced reprogramming, cultural adaptation, passage-induced mutation, and viral integration has been reported [47,48]. The maintenance of genomic stability is essential to produce distinct cell lineages because differentiated cells inherit harmful effects such as chromosomal aberrations, copy number variations (CNV), and single-nucleotide variant [48]. Such effects remained significant challenges to be addressed before used in clinics.

| Methods | Factors | Reference |
|---------|---------|-----------|
| Single lentiviral vectors expressing “stem cell cassette” with Cre-Lox transgene excision system | Oct4, Klf4, Sox2, cMyc | [24] |
| Cre-recombinase excisable DOX-inducible lentiviral vectors system | Oct4, Klf4, Sox2, cMyc | [25] |
| Repeated transfection of two expression plasmids without viral vectors system | (cDNA of Oct3/4, Sox2, Klf4) and cDNA of cMyc | [26] |
| Nonintegrating adeno viral vectors system | Oct4, Sox2, Klf4, cMyc | [27] |
| Nonintegrating Sendai virus-based vector system | Oct4, Sox2, Klf4, cMyc | [28] |
| Recombinant reprogramming proteins system (fusion of poly-arginine protein transduction domain to the C terminus of transcription factors) | Oct4, Sox2, Klf4, cMyc | [29] |
| Human artificial chromosomes (HACs) vectors (hHAC1 and iHAC2) system | Oct4, Sox2, Klf4, cMyc | [30] |
| Synthetic modified mRNA transfection system | Oct4, Sox2, Klf4, cMyc | [31] |
| Direct transfection of mature double-strand microRNAs (miRNAs) system | Combination of mir-200c, mir-302 s and mir-369 s | [32] |
| Doxycycline-inducible factors delivered by “piggyback” transposition system | Oct4, Sox2, Klf4, cMyc | [33] |
| Nonviral minicircle DNA vectors system | Oct4, Sox2, Nanog, Lin28 | [34] |
| Nonintegrating episomal plasmid vectors system | Oct4, Sox2, Nanog, Lin28, Klf4, cMyc | [35] |

Table 2: Small molecules and the mechanism that promotes reprogramming efficiency

| Molecules | Mechanism | Reference |
|-----------|-----------|-----------|
| VPA or NaB | Inhibition of HDAC | [38,39] |
| BIX-01294 (BIX) | Inhibition of G9a histone methyltransferase (G9a HMTase) | [40] |
| SB431542 plus PD0325901 | Inhibition of TGFβ receptor and MEK signaling pathway | [41] |
| SB431542 or ALK5 (A-83-01) | Inhibition of Type I TGFβ receptor | [42,43] |
| Vitamin C | Alleviates cell senescence and promotes epigenetic modifications | [44] |
| Y-27632 | Inhibition of the ROCK pathway | [45] |
| PS48 | Activation of PDK1 | [46] |

VPA: Valproic acid, NaB: Sodium butyrate, HDAC: Histone deacetylase, Rho-associated Kinase, PDK1: 3’-phosphoinositide-dependent kinase-1, MEK: MAPK/ERK Kinase

Chromosomal aberrations occurred due to selective pressure either from parental inheritance or from forced reprogramming as shown in Figure 2. A forced expression of the proto-oncogene, such as c-Myc used in reprogramming, is associated with inactivation of p53 causing genomic aberrations in iPSCs [49]. Furthermore, the demand of high metabolic rate associated with induction of oncogenic transcription factors causes elevation of oxidative stress (ER), which leads to genomic aberrations. Such aberrations can be reduced by the use of antioxidant in growth media that significantly lower the CNVs [50]. Likewise, parental cells harboring protein-coding mutations that cause cancer, remain permanent in the iPSC cell line populations [51]. In addition, only 20% of mutations are parental inheritance, while approximately 75% of coding point mutations are associated with reprogramming and persist during the subsequent passages [52].

In clinical applications, the genomic instability is of major concern which may induce teratoma, but the key factors that regulate genomic instability in iPSCs are unclear [47]. Furthermore, the level of genomic instability observed in iPSCs is comparable with the signs perceived in cancer cells [53]. Despite the instability concern, such transient aberrations and negligible report on genomic aberrations with malignant transformation will compromise the safety of iPSC-derived cell therapy in clinic. Thus, the appropriate technique should be applied to distinguish harmless aberrations and those causing tumor formations. For such classification of mutation pattern, high-resolution single-nucleotide polymorphism genotyping is recommended to monitor the acquired mutations to minimize the effects on cell therapy [54].
Application of induced pluripotent stem cell technology

iPSC technology can be directly used for developmental biology, disease modeling, drug discovery and efficacy testing, and cell transplantation. Various patient-specific iPSC lines have been generated for modeling of retinal dystrophies, such as retinitis pigmentosa, LCA, gyrate atrophy, Stargardt’s macular dystrophy, bestrophinopathies, and choroideremia [55]. Furthermore, the previous study demonstrated that rod cells derived from iPSC of retinitis pigmentosa patients showed differential responsiveness to α-tocopherol (Vitamin E) [56]. The study of human organogenesis is difficult due to inaccessibility of organs which develops in early embryos. The tracking of early eye development and organoidogenesis with fully developed laminated and functional retinal structure was generated using iPSC [57]. In addition, iPSC technology has opened new possibilities for generating continuous sources of therapeutic cells, such as RPE, retinal ganglion cells, and photoreceptors. Recently, several preclinical and clinical trials have demonstrated the safety, survival, integration, and rescue effects of clinical-grade RPE cells derived from patient-specific iPSC [58,59]. Therefore, iPSCs are promising cell sources for autologous cell transplantation, which minimizes the risks of immune rejection and the development of self-organized three-dimensional tissues using iPSC open the future possibilities for next-generation organ transplantation.

Patient-specific induced pluripotent stem cell-based eye disease modeling

Recent advances in in vitro iPSC model system are helpful resources for generating enough cells to create distinctive platforms for disease modeling, drug screening, and cell-based therapy [60]. Furthermore, human cellular models have potential benefits that overcome the limitation of the animal model, which cannot faithfully mimic human physiology. The self-renewal properties of iPSCs are promising for modeling various diseases, as other specialized primary cell lines stop proliferation after few passages in laboratory culture. Several studies used iPSCs for a wider variety of human diseases, such as genetic disorders (Down’s syndrome), neurological disorders (Parkinson’s disease), and inherited metabolic syndrome (juvenile diabetes) [60].

Usually, retinal biopsies are difficult to take or inaccessible to investigate the pathophysiology of inherited retinal diseases. Such pathological investigation became possible using patient-specific iPSCs to identify novel gene expression and silencing, drug screening and development, and cell transplantation in advanced retinal degeneration. iPSCs were used for exploring the structure of eye, such as limbal-like epithelium and corneal epithelial cells [61,62], lens-specific differentiation [63], trabecular meshwork [64], optic vesicle-like structures [65], retinal ganglion cells [66], photoreceptor cells [7], and retinal pigment epithelial cells [67]. Besides, patient-specific iPSCs were used for several inherited retinal diseases, such as age-related macular degeneration, retinitis pigmentosa, and glaucoma [68-70]. Human iPSCs were used to study early eye development and retinogenesis that recapitulate the in vivo developmental timeline using iPSC-derived retinal organoids. All retinal neurons were appropriately arranged in their proper layer, in which photoreceptors achieved sensory cilia with prominent OSD that responded the light [57]. Furthermore, RGCs were generated from iPSCs
using fibroblasts from normal tension glaucoma patient carrying a duplication of TBK1 gene [71] and multilayered optic cups from keratinocyte-derived iPSCs of patients with retinitis pigmentosa [72]. The retina precursor cells from the optic cup revealed their ability to integrate into developing mouse retina [72]. Advanced retinal diseases with severe loss of photoreceptor cells have no benefits with gene therapy, where cell transplantation remains an ultimate strategy. Therefore, the use of iPSCs-derived photoreceptors and RPE is under intense investigation to restore visual network or to arrest the loss of vision [67,72,73].

**Establishment of Induced Pluripotent Stem Cell-Derived Photoreceptor as Therapeutic Cells**

*In vitro* development of light-sensitive functional photoreceptor cells is challenging, but essential therapeutic cells for retinal degenerative diseases. In early age-related macular degeneration that is associated with RPE dysfunction, transplantation of RPE cells might be beneficial for the functional recovery of native RPE; for diseases with end-stage degeneration with loss of photoreceptors, the ultimate option is photoreceptor cell transplantation. Therefore, photoreceptors derived from iPSCs using somatic cells either from patients or from healthy donor could be effective strategies for cell-based therapy. Patient-specific photoreceptor cells could also be used to investigate the role of the mutant gene and drug screening for personalized medicine. Meanwhile, iPSC-derived photoreceptor cells from a healthy donor could be promising sources for allogeneic cell transplantation. Furthermore, the sequential development of retinal neurons provides the benefit to target disease progression at different stages in retinal degeneration [74]. Numerous studies explored the potential of photoreceptor cells generated from human iPSC as listed in Table 3. iPSC-derived photoreceptor cells have been established from various cell sources such as blood, fibroblast, and keratinocytes [56,68,72,91]. However, there is no report of iPSC-derived photoreceptor cell transplantation in human trial for the vision correction due to difficulty in establishing the robust, efficient, and stable methods for generation and purification of photoreceptor cells.

Human iPSC-derived photoreceptor cells have been generated from various diseases, such as retinitis pigmentosa, enhanced S-cone sensitivity syndrome, and gyrate atrophy as listed in Table 3. Derivative photoreceptor cells revealed the characteristic expressions, such as cell lineage markers (OTX2, CRX, RECOVERIN, RH0, B-OPSIN, and R/G OPSIN) [7,56,72], expression of proteins (VGLUT1 and SNAP-25) responsible for neurotransmitter release [65], the presence of light-responsive sensory cilia in the outer segment disc [72], and electrophysiology responses [56]. iPSC-derived photoreceptor cells were generated using somatic cells of a patient with retinitis pigmentosa harboring different mutations (RP1, RP9, PRPH2, RH0, and USH2A). Such mutations lead to degeneration of photoreceptor cells over time due to ER-stress [56,72]. Interestingly, the different types of mutation causing retinitis pigmentosa subsequently decreased in iPSC-derived rod photoreceptor cells [56,68]. However, mutant iPSC-derived rod cells undergo degeneration in *in vitro* culture that expressed the oxidative and ER stress marker responsible for the presence of disease phenotypes [56,68]. This evidence further suggests that the loss of photoreceptors in retinitis pigmentosa is postdevelopmental degeneration due to the ER stress and the unfolded protein response [68]. Furthermore, iPSC-derived retinal organoids carrying TRNT1 mutation cause high-level expression of oxidative stress molecules and abnormal accumulation of LC3-II, leading to defective autophagy [92]. The high expression of ER stress and apoptotic markers is associated with poor survival of photoreceptor cells with the rhodopsin mutation (E181K). The use of rapamycin, PP242, AICAR, NQDI-1, and salubrinal reduces the cellular stress enhancing the better survival of iPSC-derived photoreceptor precursors [82]. The data provide a novel approach for screening new drugs to attenuate degeneration in iPSC-derived photoreceptor cells, but it is still elusive whether such drugs could recover the light-responsive function of photoreceptor cells.

The *in vitro* degeneration of retinal cells and ER stress demonstrate its utility for disease modeling that recapitulates the disease phenotypes. Derivative retinal cells can be corrected for functional defect either using gene correction or pharmacological means. The previous study revealed the restoration of ornithine-δ-aminotransferase (OAT) activity in (A226V) OAT iPSC-RPE by supplementation of 600 μM Vitamin B6 and gene-corrected hiPSC-RPE cells [81]. The patient-specific iPSC carrying rhodopsin mutation (E181K) corrected using adeno viral gene transfer, which showed the ability to differentiate into rod photoreceptors [82]. Furthermore, patient-specific photoreceptor precursor cells showed the ability to integrate into the dystrophic mouse retina and develop into mature photoreceptor cells [72]. Thus, the combination of iPSCs and gene therapy approach could be used in treating various degenerative diseases causing blindness.

**Induced Pluripotent Stem Cell-Derived Photoreceptor Cell Transplantation**

Effective transplantation of derivative photoreceptor cells should meet basic criteria for high-quality clinical-grade manufacturing, safety, and efficacy. Worthwhile rapid, efficient, and consistent differentiation protocol is necessary for replacement therapy in visually challenged patients. The acquisition of mature photoreceptors in iPSC-derived retinal organoids and strategic approaches for retinal cell transplantation is shown in Figure 3a-d. However, the use of animal-derived growth factors, viral vectors during reprogramming, genomic instability and prolonged time for differentiation limit their clinical application. The use of small molecules to overcome the cross-species antigenic contamination has been suggested [77]. Furthermore, numerous studies revealed the improved differentiation protocols using chemically defined optimal culture condition for the development of retinal cell lineages and photoreceptor precursors that showed sequential expression of retinal cell markers [68,78]. Although the efficiency of differentiation was better, there was no consistency in defined molecules for induction of photoreceptors...
| Disorder | Affected gene | Cell Source | Method | Differentiation factor | Drug testing/transplantation | Functional assessment | Reference |
|----------|---------------|-------------|--------|------------------------|-----------------------------|----------------------|-----------|
| Retinitis Pigmentosa | US1A variant (Arg4192His) | Keratinocytes | Sendai virus | OCT4, SOX2, KLF4, c-MYC | Noggin, Dkk-1, IGF-1, bFGF, aFGF, B27, N2 | Multilayer eyecup-like structures and retinal rosettes (recoverin, rhodopsin, B-opsin, R/G-opsin) | [72] |
| Retinitis Pigmentosa | USH2A variant (RP1, RP9, PRPH2 or RHO gene) | Fibroblasts | Retroviral transduction | OCT3/4, SOX2, KLF4, c-MYC | Lefty-A, Dkk-1, RA, Taurine | Immature photoreceptors (CRX, recoverin); Rod cells (rhodopsin); Cone cells (opsin) | [56] |
| Retinitis Pigmentosa | RHO-G188R mutation | Fibroblasts | Sendai virus | OCT4, SOX2, KLF4, c-MYC | Lefty-A, Dkk-1, RA, Taurine | Photoreceptor precursors (recoverin, CRX); Rod cells (rhodopsin) | [68] |
| Undefined | Normal | Fibroblasts | Lentiviral transduction | OCT4, SOX2, KLF4, c-MYC | B27, N2, OCT3, SOX2, KLF4, c-MYC | Photoreceptor precursors (OTX2, CRX, recoverin); Rod cells (rhodopsin) | [7] |
| Enhanced S-cone sensitivity syndrome (ESCS) | NR2E3 mutations | Fibroblasts | Sendai virus | OCT4, SOX2, KLF4, c-MYC | IWR1e, CHIR, SAG, N2, DAPT | Photoreceptor precursors (OTX2, CRX, recoverin); Rod cells (rhodopsin) | [75] |
| MAK-associated Retinitis Pigmentosa | Homozygous for Alu insertion in MAK lacking exon 9 transcript | Fibroblasts | Retroviral transduction | OCT4, SOX2, KLF4, c-MYC | SB-431542, SB-431542, N2, OCT3, SOX2, KLF4, c-MYC | Not performed | [77] |
| Undefined | N/A | N/A | N/A | N/A | N/A | N/A | [76] |
| Undefined | N/A | N/A | N/A | N/A | N/A | N/A | [78] |
| Undefined | N/A | N/A | N/A | N/A | N/A | N/A | [79] |
| Disorder                  | Affected gene | Cell Source                        | Method                                      | Differentiation factor | Cell types and markers                                                                 | Drug testing/transplantation | Functional assessment                                                                 | Reference |
|---------------------------|---------------|------------------------------------|---------------------------------------------|------------------------|-----------------------------------------------------------------------------------------|------------------------------|----------------------------------------------------------------------------------------|-----------|
| Undefined                 | N/A           | Corneal fibroblast                 | STEMCAA lentivirus OCT4, SOX2, KLF4, MYC    | B27, N2, RA, Taurine, bFGF, aFGF, SHH                                               | Photoreceptor precursors (CRX, recoverin) Rod cells (NRL, NR2E3, RORβ, SW opsin) | Not Performed                  | N/A                                                                                     | [80]      |
| Undefined                 | N/A           | hiPSC lines; fibroblasts, cord blood, keratinocytes | Lentivirus SOX2, OCT4, NANOg, LIN28. Episomes SOX2, OCT4, KLF4, MYC, NANOg, LIN28, SV40T | Heparin, N2, B27, Taurine, RA | Photoreceptor precursors (Ot×2, recoverin) Rod cells (rhodopsin); cone cells (S-opsin, L/M-opsin) | Not Performed                 | Retinal organoids acquired mature photoreceptors with functional domains containing an outer segment disc that were responsive to lights | [57]      |
| Healthy donor             | N/A           | Blood (activated T cells)          | Retroviral transduction; 3 bicistronic MMLV constructs: (OCT4, SOX2), (c-MYC, KLF4), and (NANOg, LIN28) | Heparin, N2, B27 | Photoreceptor precursors (CRX, recoverin) Rod cells (rhodopsin); cone cells (S-opsin) | Not performed                 | In vitro synaptogenesis was recapitulated in hiPSC-derived optic vesicles. CX36 required for electrical synapses were upregulated in optic vesicles | [65]      |
| Gyrate atrophy            | N/A           | hiPSC lines, gyrate atrophy fibroblasts | Lentiviral transduction OCT4, SOX2, NANOg, LIN28, c-MYC, KLF4 | Noggin, Dkk-1, B27, N2 | Photoreceptor precursors (OTX2, CRX, NRL, RORβ, recoverin) Phototransduction (CNGA1, A3, B1 and B3, RETGC, ODE6B, arrestin). Photoreceptor-like cells showed electrophysiological responses | Not Performed                 | Gene-corrected hiPSC-RPE showed normal level of ornithine-δ-aminotransferase (OAT) activity | [81]      |
| Retinitis pigmentosa      | Rhodopsin     | Fibroblasts                         | Retroviral transduction OCT3/4, SOX2, KLF4, c-MYC | N2, Noggin, Dkk-1, IGF-1 | NRL-positive rod cells DNA damage-inducible transcript (Bip and CHOP) expressed, Rhodopsin E181K mutation was responsible for the loss of rod cells | Drug Screening: mTOR inhibitors (rapamycin and PP242), AMPK activators (AICAR), ASK1 inhibitors (ND2I-1), and inhibitors for eIF2α phosphatase and protein synthesis (sulubrinal) | Suppression of E181K mutant rhodopsin-related cell loss by mTOR inhibition, AMPK activation, ASK1 inhibition, or the suppression of protein synthesis | [82]      |
| Undefined                 | N/A           | hiPSC cell lines                   | N/A                                         | N2, Heparin, B27, BMP4, Wnt3A, SU5402 | Photoreceptor precursors (CRX, recoverin) Cone-specific opsin | Not performed                 | N/A                                                                                     | [83]      |
| Undefined                 | N/A           | hiPSC cell lines                   | mRNA reprogramming Kit, Episomal vectors    | B27, N2, Insulin, Noggin, BDNF, CNF, RA, DAPT | Photoreceptor progenitors (CRX, NRL, NR2E3), Rod cells (rhodopsin, recoverin, and phosphodiesterase 6 alpha) | Subretinal space; Rd1 mice with end-stage retinal degeneration | Differentiated into cell photoreceptors, formed cell layer, interact with host retina and visual functions was partially restored | [74]      |
| Disorder          | Affected gene | Cell Source                        | Method                                                                 | Differentiation factor | Cell types and markers                                      | Drug testing/transplantation | Functional assessment                                                                 | Reference |
|-------------------|---------------|------------------------------------|------------------------------------------------------------------------|------------------------|-------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------------------------|-----------|
| Undefined         | N/A           | Fibroblasts                         | OriP/EBNA1-based episomal vectors pEP4EO2SEN2K, pEP4EO2SET2K, and pCEP4-M2L | N2, FG2, DAPT          | Photoreceptor precursors (OTX2, CRX, NRL recoverin)          | Not performed               | Notch pathway inhibition accelerated the generation of photoreceptor precursors        | [84]      |
| None              | N/A           | hiPS cell line (NCL1), cord blood-derived CD34+ | Episomal plasmids                                                     | N1, Dkk-1, Noggin, IGFl, IWR1, SB431542, LDN193189 | Photoreceptor precursors (OTX2, CRX, BLIMP1, AIPL1, recoverin) | Subretinal space; IL2γ−/− mice (B6.129S4-Il2rgm1WjlJ) | Photoreceptor precursor cells integrated into the host retina with synaptic end-feet to plexiform layer | [85]      |
| None              | N/A           | hiPS cell line (IMR90-4)            | N/A                                                                   | B27, Taurine, RA, N2    | Photoreceptor precursors (Recoverin)                         | Not performed               | Bioreactor culture conditions improved retinal lamination and increased the yield of photoreceptors | [86]      |
| None              | N/A           | hiPS cell line (H9, H1, IMR90-4)    | N/A                                                                   | N2, B27, Taurine, RA    | Photoreceptor precursors (OTX2, CRX, NRL recoverin)          | Subretinal space; Cone cells transplantation into Nrl−/−, and AipII−/− mice | Cone precursors incorporated into host cone-rich retina. Also, cones have the potential to replace lost photoreceptors in end-stage retinal degeneration | [87]      |
| None              | N/A           | hiPS cell line (hiPSC-2 clone), fibroblasts | N/A                                                                   | N2, B27, FG2            | Photoreceptor precursors (CRX, Recoverin, CD73)              | Trans-vitreal injection; hemizygous P23H rats along Cyclosporine A (210 mg/L) | Transplantation of CD73+cells showed no significant functional improvement | [88]      |
| Healthy donor     | N/A           | hiPS cell lines (UE017, UE022, and UC005), urine cells | N/A                                                                   | B27, N2, Taurine        | Photoreceptor precursors (OTX2)                             | Not performed               | Matured rod and cone cells acquisition in retinal organoids without the addition of RA | [89]      |
| None              | N/A           | NHEK primary cell line              | Sendai virus OCT4, SOX2, KLF4, c-MYC                                    | B27, N2, DAPT, Taurine  | Photoreceptor precursors (OTX2, CRX, recoverin)              | Not performed               | Aberrant-hiPSC differentiated into retinal organoids that acquired matured photoreceptors | [90]      |

N/A: Not available
from iPSC. Thus, the optimization of minimal culture conditions which endogenously upregulate the specific transcription factors of retinal cells is necessary. The key factors such as B27, N2, DKK1, and Noggin enhance the early stage differentiation of iPSC into retinal and photoreceptor precursors [79]. However, with improvement in the methodology for iPSC generation without viral vectors [Table 1], feeder-free culture conditions and chemically defined directed differentiation approaches for efficient generation of photoreceptor precursor cells have offered the platform for modeling human diseases.

The transplantation of postnatal photoreceptor precursors and PSC-derived photoreceptor precursors showed the proof of its potential benefit for the restoration of visual functions [7,93,94]. Transplantation of photoreceptor cells derived from iPSC in rd1 mouse model of end-stage retinitis pigmentosa revealed the robust cell survival, developed a mature outer nuclear layer (ONL), and connected to interneurons improving the visual function [74]. However, the functional restoration after transplantation could be associated with RNA and/or protein transfer between graft and host photoreceptors; instead of transplanted photoreceptors migrating and integrating into the photoreceptor layer of recipients [95,96], these observations raise the possibility of material transfer as an alternative strategy for the treatment of retinal disorders. Surprisingly, CD73+ photoreceptor precursors derived from human iPSC transplanted into rat eyes revealed the capacity to survive and mature in proximity to host inner retina without significant functional improvement by electoretinography [88]. They suggested that more suitable transplantation strategies and closely related species (such as nonhuman primates) may improve the functionality of CD73+ cells after transplantation [88]. Further, the purification of transplantable photoreceptors using fluorescence-activated cell sorting and magnetic-activated cell sorting can be effective strategies for obtaining approximately 90% of pure cells, avoiding the possible risk of teratoma formation [7,88]. In addition, PSC-derived retinal organoids in three-dimensional culture systems offer the accessibility to the human cells such as photoreceptors and RPE for future clinical applications in degenerative diseases [97,98]. Furthermore, transplantable photoreceptor cells could be isolated from heterogeneous cells layered in the retinal organoids using novel label-free sorting approaches based on the inherent characteristics, such as mechanical and morphorheological properties [97]. Moreover, transplantation studies have revealed that photoreceptor precursors can differentiate into mature photoreceptor cells, and migrate to host ONL, in which donor cells acquire synaptogenic potential and initiate retinal synaptic circuitry with naïve photoreceptors via cellular integration [97,98]. While sensory photoreceptor cell transplantation has been the center of focus, it is essential to include RPE cells for successful and sustainable recovery of vision in certain diseases [99]. Thus, cotransplantation of RPE and photoreceptors provides a favorable environment for incorporation of donor cells as shown in Figure 3d.

**Conclusions**

iPSC-derived photoreceptor cells are promising and future hope for effective cell-based therapy in end-stage retinal diseases. However, based on numerous publications, the hype has been created in the scientific community and to the public
indicating the success of photoreceptor cell transplantation. Till date, there is no evidence on human studies showing successful and effective photoreceptor transplantation that reversed the loss of vision. Furthermore, similar data on transplantation, such as cell survival, integration, and trophic support for improving visual functions, were interpreted differently. More preclinical studies are required to claim the science behind the success of iPSC derivative transplantation.

Financial support and sponsorship
The Buddhist Tzu Chi Medical Foundation grants (TCMMP104-05-01 and TCMF-EP-108-01) supported Institute of Eye Research, Hualien Tzu Chi Hospital, Hualien, Taiwan.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Heavner W, Pevny L. Eye development and retinogenesis. Cold Spring Harb Perspect Biol 2012;4: pii: a008391.
2. Bassett EA, Wallace VA. Cell fate determination in the vertebrate retina. Trends Neurosci 2012;35:565-73.
3. Young RW. Cell differentiation in the retina of the mouse. Anat Rec 1985;212:199-205.
4. Bramall AN, Wright AF, Jacobson SG, McInnes RR. The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders. Annu Rev Neurosci 2010;33:441-72.
5. Pacione LR, Szego MJ, Ikeda S, Nishina PM, McInnes RR. Progress toward understanding the genetic and biochemical mechanisms of inherited photoreceptor degenerations. Annu Rev Neurosci 2003;26:657-70.
6. Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS. Photoreceptor degeneration: Genetic and mechanistic dissection of a complex trait. Nat Rev Genet 2010;11:273-84.
7. Lamba DA, McUsic A, Hirata RK, Wang PR, Russell D, Reh TA. Generation, purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS One 2010;5:e8763.
8. McBeek JK, Palczewski K, Baehr W, Pepperberg DR. Confronting complexity: The interlink of phototransduction and retinoid metabolism in the vertebrate retina. Prog Retin Eye Res 2001;20:469-529.
9. Fain GL, Hardie R, Laughlin SB. Phototransduction and the evolution of photoreceptors. Curr Biol 2010;20:R114-29.
10. MacLaren RE, Pearson RA, MacNeil A, Douglas RH, Salt TE, Akimoto M, et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006;444:203-7.
11. Hartong DT, Berson EL, Dryja TP. Phototransduction and the clinical phenotype of leber congenital amaurosis. Br J Ophthalmol 2010;94:1281-7.
12. Jackson GR, Owsley C, Curcio CA. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev 2002;1:381-96.
13. Traboulsi EI. The Marshall M. Parks memorial lecture: Making sense, the challenges and promises of next-generation sequencing. Genome Med 2013;5:84.
14. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.
15. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
16. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2008;318:1917-20.
17. Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Martin G, Kapryanov S, et al. Generation of mice derived from induced pluripotent stem cells. J Vis Exp 2012;69:e4003.
18. Shibata Y, Gomibuchi T, Seto T, Wada Y, Ichimura H, Tanaka Y, et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 2010;468:388-91.
19. Ezhaki T, Telugu BP, Alexenko AP, Sachdev S, Sinha S, Roberts RM. Derivation of induced pluripotent stem cells from pig somatic cells. Proc Natl Acad Sci U S A 2009;106:10993-8.
20. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012;481:295-305.
21. Mohiduki Y, Okita K. Methods for iPS cell generation for basic research and clinical applications. Biotechnol J 2012;7:789-97.
22. Gonzalez F, Boué S, Izpisúa Belmonte JC. Methods for making induced pluripotent stem cells. Reprogramming à la carte. Nat Rev Genet 2011;12:231-42.
23. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced pluripotent stem cell generation using a lentiviral stem cell cassette. Stem Cells 2009;27:543-9.
24. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-77.
25. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322:945-53.
26. Stadtfeld M, Nagaya Y, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-9.
27. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009;85:348-62.
28. Zhou H, Wu S, Joo YJ, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-4.
29. Hiratsuaka M, Uno N, Ueda K, Kuroasaki H, Imaoka N, Kazuki K, et al. Integration-free iPS cells engineered using human artificial chromosome vectors. PLoS One 2011;6:e25961.
30. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-30.
31. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011;8:633-8.
32. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, et al. PiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-70.
33. Narsih KH, Jia F, Robbins RC, Kay MA, Longaker MT, Wu JC. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc 2011;6:78-88.
34. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324:797-801.
35. Ebrahimi B. Reprogramming barriers and enhancers: Strategies to enhance the efficiency and kinetics of induced pluripotency. Cell Regen (Lond) 2015;4:10.
36. Feng B, Ng JH, Heng JC, Ng HH. Molecules that promote or enhance reprogramming: A comprehensive review. J Cell Mol Med 2010;14:2439-55.
37. Fain GL, Hardie R, Laughlin SB. Phototransduction and the evolution of photoreceptors. Curr Biol 2010;20:R114-29.
38. MacLaren RE, Pearson RA, MacNeil A, Douglas RH, Salt TE, Akimoto M, et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006;444:203-7.
39. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368:1795-809.
40. Jackson GR, Owsley C, Curcio CA. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev 2002;1:381-96.
41. Traboulsi EI. The Marshall M. Parks memorial lecture: Making sense of early-onset childhood retinal dystrophies – The clinical phenotype of leber congenital amaurosis. Br J Ophthalmol 2010;94:1281-7.
42. Ratnapriya R, Swaroop A. Genetic architecture of retinal and macular degenerative diseases: The promise and challenges of next-generation sequencing. Genome Med 2013;5:84.
43. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.
44. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009;4:301-12.
38. Ware CB, Wang L, Mecham BH, Shen L, Nelson AM, Bar M, et al. Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell 2009;4:359-69.
39. Huangfu D, Osafune K, Maehr R, Gao W, Eijkelenboom A, Chen S, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008;26:1269-75.
40. Shi Y, Do JT, Desponts C, Hahn HS, Schölter HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;2:525-58.
41. Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R, et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009;6:805-8.
42. Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009;4:16-9.
43. Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, et al. A small molecule inhibitor of tgf-beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009;5:491-503.
44. Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010;6:71-9.
45. Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 2007;25:681-6.
46. Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, Lin T, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010;7:651-5.
47. Yoshihara M, Hayashizaki Y, Murakawa Y. Genomic instability of iPSCs: Challenges towards their clinical applications. Stem Cell Rev 2017;13:7-16.
48. Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: Potential causes and implications for application. Cell Stem Cell 2013;13:149-59.
49. Pasi CE, Dereli-Öz A, Negrini S, Friedli M, Fragola G, Lombardo A, et al. Genomic instability in induced stem cells. Cell Death Differ 2011;18:745-53.
50. Ji J, Sharma V, Qi S, Guarch ME, Zhao P, Luo Z, et al. Antioxidant supplementation reduces genomic aberrations in human induced pluripotent stem cells. Stem Cell Reports 2014;2:24-41.
51. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471:63-7.
52. Ji J, Ng SH, Sharma V, Neculai D, Hussein S, Sam M, et al. Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells 2012;30:435-40.
53. Pera MF. Stem cells: The dark side of induced pluripotency. Nature 2011;471:46-7.
54. Peterson SE, Loring JF. Genomic instability in pluripotent stem cells: Implications for clinical applications. J Biol Chem 2014;289:4578-84.
55. Foltz LP, Clegg DO. Patient-derived induced pluripotent stem cells for modelling genetic retinal dystrophies. Prog Retin Eye Res 2019;68:54-66.
56. Jin ZB, Okamoto S, Okada F, Homma K, Assawachananont J, Hirami Y, et al. Modeling retinal degeneration using patient-specific induced pluripotent stem cells. PLoS One 2011;6:e17084.
57. Zhong X, Gutierrez C, Xue T, Hampton C, Vergara MN, Cao LH, et al. Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs. Nat Commun 2014;5:4047.
58. Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daionon T, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med 2017;376:1038-46.
59. Sharma R, Khristov V, Rising A, Jha BS, Dejene R, Hotaling N, et al. Clinical-grade stem-cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs. Sci Transl Med 2019;11:eaat5580.
60. Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet 2019;20:377-88.
61. Hayashi R, Ishikawa Y, Ito M, Kageyama T, Takashiba K, Fujisaka T, et al. Generation of corneal epithelial cells from induced pluripotent stem cells derived from human dermal fibroblast and corneal limbal epithelium. PLoS One 2012;7:e45435.
62. Sareen D, Saghiizadeh M, Ornelas L, Winkler MA, Narwani K, Sahabian A, et al. Differentiation of human limbal-derived induced pluripotent stem cells into limbal-like epithelium. Stem Cells Transl Med 2014;3:1002-12.
63. Qiu X, Yang J, Liu T, Jiang Y, Le Q, Lu Y. Efficient generation of lens progenitor cells from cataract patient-specific induced pluripotent stem cells. PLoS One 2012;7:e32612.
64. Ding QJ, Zhu W, Cook AC, Anfinson KR, Tucker BA, Kuehn MH. Induction of trabecular meshwork cells from induced pluripotent stem cells. Invest Ophthalmol Vis Sci 2014;55:7065-72.
65. Phillips MJ, Wallace KA, Dickerson SJ, Miller MJ, Verhoeven AD, Martin JM, et al. Blood-derived human iPSC cells generate optic vesicle-like structures with the capacity to form retinal laminae and develop synapses. Invest Ophthalmol Vis Sci 2012;53:2007-19.
66. Tanaka T, Yokoi T, Tamalu F, Watanabe S, Nishina S, Azuma N. Generation of retinal ganglion cells with functional axons from mouse embryonic stem cells and induced pluripotent stem cells. Invest Ophthalmol Vis Sci 2016;57:3348-59.
67. Buchholz DE, Pennington BO, Croze RH, Himman CR, Coffey PJ, Clegg DO. Rapid and efficient directed differentiation of human pluripotent stem cells into retinal pigmented epithelium. Stem Cells Transl Med 2013;2:384-93.
68. Jin ZB, Okamoto S, Xiang P, Takahashi M. Integration-free induced pluripotent stem cells derived from retinitis pigmentosa patient for disease modeling. Stem Cells Transl Med 2012;1:503-9.
69. Saini JS, Corneo B, Miller JD, Kiehl TR, Wang Q, Boles NC, et al. Nicotinamide ameliorates disease phenotypes in a human iPSC model of age-related macular degeneration. Cell Stem Cell 2017;20:635-47.
70. Ohlemacher SK, Sridhar A, Xiao Y, Hochstetler AE, Sarfarazi M, Cummins TR, et al. Stemwise differentiation of retinal ganglion cells from human pluripotent stem cells enables analysis of glaucomatous neurodegeneration. Stem Cells 2016;34:1533-62.
71. Tucker BA, Solivan-Tinpe F, Roos BR, Anfinson KR, Robin AL, Wiley LA, et al. Duplication of TBK1 stimulates autophagy in iPSC-derived retinal cells from a patient with normal tension glaucoma. J Stem Cell Res Ther 2014;3:161.
72. Tucker BA, Mullins RF, Streb LM, Anfinson K, Eyestone ME, Kaalberg E, et al. Patient-specific iPSC-derived photoreceptor precursor cells as a means to investigate retinitis pigmentosa. Elife 2013;2:e00824.
73. Kamao H, Mandai M, Okamoto S, Sakai N, Suga A, Sugita S, et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports 2014;2:205-18.
74. Barnea-Cramer AO, Wang W, Lu SJ, Singh MS, Luo C, Huo H, et al. Function of human pluripotent stem cell-derived photoreceptor progenitors in blind mice. Sci Rep 2016;6:29784.
75. Wiley LA, Burmicht ER, DeLuca AP, Anfinson KR, Cranston CM, Kaalberg EE, et al. CGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness. Sci Rep 2016;6:30742.
76. Tucker BA, Scheetz TE, Mullins RF, DeLuca AP, Hoffmann JM, Johnston RM, et al. Exome sequencing and analysis of induced pluripotent stem cells identify the cilia-related gene male germ cell-associated kinase (MAK) as a cause of retinitis pigmentosa. Proc Natl Acad Sci U S
A 2011;108:E569-76.
77. Osakada F, Jin ZB, Hirami Y, Ikeda H, Danjyo T, Watanabe K, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci 2009;122:3169-79.
78. Hirami Y, Osakada F, Takahashi K, Okita K, Yamanaka S, Ikeda H, et al. Generation of retinal cells from mouse and human induced pluripotent stem cells. Neurosci Lett 2009;458:126-31.
79. Mellough CB, Sernagor E, Moreno-Gimeno I, Steel DH, Lako M. Efficient stage-specific differentiation of human pluripotent stem cells toward retinal photoreceptor cells. Stem Cells 2012;30:673-86.
80. Boucherie C, Mukherjee S, Henckaerts E, Thrasher AJ, Sowden JC, Ali RR. Brief report: Self-organizing neuroepithelium from human pluripotent stem cells facilitates derivation of photoreceptors. Stem Cells 2013;31:408-14.
81. Meyer JS, Howden SE, Wallace KA, Verhoeven AD, Wright LS, Capowski EE, et al. Optic vesicle-like structures derived from human pluripotent stem cells facilitate a customized approach to retinal disease treatment. Stem Cells 2011;29:1206-18.
82. Yoshida T, Ozawa Y, Suzuki K, Yuki K, Ohyama M, Akamatsu W, et al. The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa. Mol Brain 2014;7:45.
83. Meyer JS, Shearer RL, Capowski EE, Wright LS, Wallace KA, McMillan EL, et al. Modeling early retinal development with human embryonic and induced pluripotent stem cells. Proc Natl Acad Sci U S A 2009;106:16698-703.
84. Reichman S, Terray A, Slembrouck A, Nanteau C, Orieux G, Habeler W, et al. A comparative view on human somatic cell sources for iPSC generation. Stem Cells Int 2018;2018:4968658.
85. Zhu J, Reynolds J, Garcia T, Cifuentes H, Chew S, Zeng X, et al. Generation of transplantable retinal photoreceptors from a current good manufacturing practice-manufactured human induced pluripotent stem cell line. Stem Cells Transl Med 2018;7:210-9.
86. Ovando-Roche P, West EL, Branch MJ, Sampson RD, Fernando M, Munro P, et al. Use of bioreactors for culturing human retinal pigmented epithelium. Proc Natl Acad Sci U S A 2014;111:8518-23.
87. Zhu J, Reynolds J, Garcia T, Cifuentes H, Chew S, Zeng X, et al. Generation of transplantable retinal photoreceptors from a current good manufacturing practice-manufactured human induced pluripotent stem cell line. Stem Cells Transl Med 2018;7:210-9.
88. Gagliardi G, Ben M’Barek K, Chaffiol A, Slembrouck-Brec A, Conart JB, Nanteau C, et al. Characterization and transplantation of CD73-positive photoreceptors isolated from human iPSC-derived retinal organoids. Stem Cell Reports 2018;11:665-80.
89. Li G, Xie B, He L, Zhou T, Gao G, Liu S, et al. Generation of retinal organoids with mature rods and cones from urine-derived human induced pluripotent stem cells. Stem Cells Int 2018;2018:4968658.
90. Shrestha R, Wen YT, Ding DC, Tsai RK. Aberrant hiPSCs-derived from human keratinocytes differentiates into 3D retinal organoids that acquire mature photoreceptors. Cells 2019;8. pii: E36.
91. Raab S, Klingenstein M, Liebau S, Linta L. A comparative view on human somatic cell sources for iPSC generation. Stem Cells Int 2014;2014:768391.
92. Sharma TP, Wiley LA, Whitmore SS, Anfinson KR, Cranston CM, Oppedal DJ, et al. Patient-specific induced pluripotent stem cells to evaluate the pathophysiology of TRNT1-associated retinitis pigmentosa. Stem Cell Res 2017;21:58-70.
93. Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, et al. Restoration of vision after transplantation of photoreceptors. Nature 2012;485:99-103.
94. Gonzalez-Cordero A, West EL, Pearson RA, Duran Y, Carvalho LS, Chu CJ, et al. Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. Nat Biotechnol 2013;31:741-7.
95. Santos-Ferreira T, Llonch S, Borsch O, Postel K, Haas J, Ader M. Retinal transplantation of photoreceptors results in donor-host cytoplasmic exchange. Nat Commun 2016;7:13028.
96. Pearson RA, Gonzalez-Cordero A, West EL, Ribeiro JR, Aghaizu N, Goh D, et al. Donor and host photoreceptors engage in material transfer following transplantation of post-mitotic photoreceptor precursors. Nat Commun 2016;7:13029.
97. Gasparini SJ, Llonch S, Borsch O, Ader M. Transplantation of photoreceptors into the degenerative retina: Current state and future perspectives. Prog Retin Eye Res 2019;69:1-37.
98. Gagliardi G, Ben M’Barek K, Goureau O. Photoreceptor cell replacement in macular degeneration and retinitis pigmentosa: A pluripotent stem cell-based approach. Prog Retin Eye Res 2019;71:1-25.
99. Lorach H, Kang S, Bhuckory MB, Trouillet A, Dalal R, Marmor M, et al. Transplantation of mature photoreceptors in rodents with retinal degeneration. Transl Vis Sci Technol 2019;8:30.